Bio Pharma Dive
OCTOBER 17, 2023
One month after Roche’s Genentech inked a similar deal, the Swiss pharma is now paying $50 million to work with Monte Rosa on molecular glue medicines for cancer and neurological diseases.
Pharmaceutical Technology
OCTOBER 17, 2023
In October 2023, Novo Nordisk announced that its trial studying Ozempic (semaglutide) in diabetic CKD patients, will come to a halt almost a year prior to its planned completion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 17, 2023
Nucleus RadioPharma, a contract developer and manufacturer, is expanding at a time when investment is pouring into the radiopharmaceutical drug field.
Pharmaceutical Technology
OCTOBER 17, 2023
As AI applications in drug manufacturing widen, Leucine’s digital twin of the shop floor helps automate compliance and improve safety.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 17, 2023
At least 10% of people infected with SARS-CoV-2, the virus that causes COVID, have symptoms that last more than four weeks after the infection.
Pharmaceutical Technology
OCTOBER 17, 2023
SpliceBio will license Spark Therapeutics’ propriety protein splicing platform to develop a gene therapy for renal disease.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 17, 2023
The Indian Council of Medical Research (ICMR) has invited expression of interest (EOI) from Indian scientists and researchers to accelerate screening, early diagnosis and treatment of cancer at the district level.
Bio Pharma Dive
OCTOBER 17, 2023
Tuesday’s earnings were the first since J&J officially split off its consumer drug business, now the publicly traded company Kenvue.
Pharmaceutical Technology
OCTOBER 17, 2023
The extended agreement will focus on developing checkpoint inhibitors in cancer, with two anti-PD1 antibodies in preclinical development.
Bio Pharma Dive
OCTOBER 17, 2023
The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.
Pharmaceutical Technology
OCTOBER 17, 2023
The US BARDA contract will sponsor the development of the company’s plasma gelsolin for treating acute respiratory distress syndrome.
Pharma Times
OCTOBER 17, 2023
The two projects will investigate the potential causes of Parkinson’s disease - News - PharmaTimes
Fierce Pharma
OCTOBER 17, 2023
Editor's note: This is an evolving story. Please check back on Oct. 23 when the full data of MARIPOSA are presented at ESMO 2023. | A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the EGFR king.
Pharmaceutical Technology
OCTOBER 17, 2023
The latest Keytruda/chemotherapy approval marks the sixth setting in NSCLC where the PD-1 inhibitor is FDA-approved.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
OCTOBER 17, 2023
The condition is responsible for 2,200 annual deaths in the UK - News - PharmaTimes
Pharmaceutical Technology
OCTOBER 17, 2023
The Netherlands-based company’s treatment has been awarded the designation by the US FDA following a successful Phase I trial.
Fierce Pharma
OCTOBER 17, 2023
The third time’s the charm for Ardelyx and its chronic kidney disease med Xphozah (tenapanor). | After the FDA requested more data in 2021, Ardelyx instead defended its drug's profile through two appeals and an advisory committee meeting. Now, the company can celebrate a long-awaited win.
Pharmaceutical Technology
OCTOBER 17, 2023
LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
pharmaphorum
OCTOBER 17, 2023
VR-based navigation test may detect Alzheimer’s Phil.
Pharmaceutical Technology
OCTOBER 17, 2023
The US FDA has granted a priority review to the sNDA filed by AstraZeneca for its Tagrisso (osimertinib) along with chemotherapy
pharmaphorum
OCTOBER 17, 2023
In this latest instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with life sciences advisor Randall Hein, CEO of Heinsight LLC, and health sciences marketing expert Krystle Buntemeyer, CEO of SCORR Marketing, about the trends and changes for health sciences marketing over the past few years.
Pharmaceutical Technology
OCTOBER 17, 2023
Vaxcyte has signed a new commercial agreement with Lonza for the global manufacture of broad-spectrum PCVs.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
OCTOBER 17, 2023
As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly diagnosed unresectable liver cancer—approved in China back in February—the partners a | As Elevar Therapeutics and Hengrui Pharmaceuticals await an FDA decision on their combination therapy for newly-diagnosed unresectable liver cancer—approved in China back in February—the partners are lining up a new global commercialization pact.
Pharmaceutical Technology
OCTOBER 17, 2023
Novo Nordisk has signed an agreement to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences for $1.3bn.
pharmaphorum
OCTOBER 17, 2023
Roche builds gene therapy portfolio with SpliceBio deal Phil.
Fierce Pharma
OCTOBER 17, 2023
Even as pharma giants try to get a handle on the Inflation Reduction Act in the U.S., drug pricing tensions continue to flare overseas. | With the U.K. working to tweak the Statutory Scheme for branded medicines, the Association of the British Pharmaceutical Industry is making its discontent known—and it’s managed to rally more than 20 major drugmakers to its cause.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
OCTOBER 17, 2023
Owkin signs up another pharma partner for its AI platform Phil.
Drug Patent Watch
OCTOBER 17, 2023
This chart shows the pharmaceutical companies with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
OCTOBER 17, 2023
After failing its primary endpoint of progression-free survival, new data shows UV1 plus Bristol Myers Squibb’s Opdivo and Yervoy reduces risk of death by 27% over the checkpoint inhibitors alone.
Rethinking Clinical Trials
OCTOBER 17, 2023
What Are the Reasons to Randomize Clusters Instead of Individuals? Description Dr. Liz Turner discusses the reasons to randomize clusters instead of individuals. Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post What Are the Reasons to Randomize Clusters Instead of Individuals?
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
162 
Let's personalize your content